Roquefort Therapeutics (LON:ROQ) Trading 3.9% Higher – Here’s Why

Posted by ABMN Staff on Jan 5th, 2026

Shares of Roquefort Therapeutics plc (LON:ROQ – Get Free Report) traded up 3.9% during trading on Monday . The stock traded as high as GBX 1.50 and last traded at GBX 1.46. 1,882,007 shares were traded during trading, an increase of 14% from the average session volume of 1,649,303 shares. The stock had previously closed at GBX 1.40.

Roquefort Therapeutics Stock Up 3.9%

The business’s fifty day moving average price is GBX 1.58 and its two-hundred day moving average price is GBX 1.66. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79. The firm has a market capitalization of £2.29 million, a P/E ratio of -2.31 and a beta of 0.05.

Insiders Place Their Bets

In other news, insider Dr Darrin Disley purchased 5,000,000 shares of the business’s stock in a transaction on Friday, November 21st. The shares were acquired at an average cost of GBX 170 per share, with a total value of £8,500,000. 23.53% of the stock is currently owned by company insiders.

Roquefort Therapeutics Company Profile

(Get Free Report)

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.